ASN-002

AXP000149.1 · Viral vector gene therapy

Platform
adenovirus (non-replicating, IFN-gamma)
Targets
IFNG
Originator
Transgene
Sponsor
Ascend Biopharmaceuticals

Names

NameTypeSource
ASN-002preferred name, codecurator, ncit
Ad-IFNg ambiguoussynonymncit
TG1042former codencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus
Replication
non replicating
Modifications
non-replicating adenoviral vector encoding human interferon gamma
Transgenes
IFNG
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C66972

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04416516Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorCompletedPhase 22020-07-162024-02-1421Basal Cell Carcinoma; Basal Cell Nevus Syndrome
NCT03728504Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand EczemaCompletedPhase 22019-01-032020-04-2997Chronic Hand Dermatitis
NCT03641573Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 12018-10-112018-10-218Healthy Volunteer
NCT03654755Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisTerminatedPhase 22018-09-292019-10-29162Atopic Dermatitis
NCT03531957Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)CompletedPhase 22018-07-052019-07-22244Atopic Dermatitis
NCT03208296Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)SuspendedPhase 1/22017-12-012024-12-3124Basal Cell Carcinoma in Basal Cell Nevus Syndrome
NCT03139981A Study To Evaluate ASN002 In Subjects With Atopic DermatitisCompletedPhase 12017-04-122017-11-0536Dermatitis Eczema; Dermatitis, Atopic; Dermatitis, Eczematous
NCT02853643Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy VolunteersCompletedPhase 12016-072016-1122Healthy Volunteers
NCT02550678A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell CarcinomaCompletedPhase 1/22015-092017-1116Basal Cell Nevus Syndrome; Nodular Basal Cell Carcinoma of Skin; Skin Neoplasm
NCT02440685A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedPhase 1/22015-052018-0651B-Cell Chronic Lymphocytic Leukemia; B-Cell Leukemia, Chronic; B-Lymphocytic Leukemia, Chronic; Cancer; Chronic Idiopathic Myelofibrosis; Chronic Lymphocytic Leukemia; Idiopathic Myelofibrosis; Leukemia, Lymphocytic, Chronic; Leukemia, Lymphocytic, Chronic, B Cell; Lymphoma, B-cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Malignant; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T Cell, Peripheral; Myelofibrosis; Neoplasm; Peripheral T-Cell Lymphoma; T-Cell Lymphoma, Peripheral; Tumor
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT01082887A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)TerminatedPhase 1/22010-012012-1018Metastatic Melanomaname in title: Ad-IFNg

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39760239Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis.Allergy2025cited by trial NCT03728504
PMID 25846669Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients.Cancer immunology, immunotherapy : CII2015name in title: TG1042
PMID 24586226TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial.PloS one2014name in title: TG1042
PMID 24063735Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042.Journal of translational medicine2013name in title: TG1042
PMID 20372104Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.Molecular therapy : the journal of the American Society of Gene Therapy2010name in title: TG1042
PMID 15161670Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.Blood2004name in abstract: TG1042

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 17621880Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.Current opinion in investigational drugs (London, England : 2000)2007name in title: TG1042
PMID 15333750Gene-based vaccines and immunotherapeutics.Proceedings of the National Academy of Sciences of the United States of America2004name in abstract: TG1042

Notes

Adenovirus encoding human interferon gamma, injected into skin tumours. Developed by Transgene as TG1042 for cutaneous T-cell lymphoma, later taken forward by Ascend Biopharmaceuticals as ASN-002 for basal cell carcinoma (phase 2). Adenovirus serotype not verified.

How to cite

ASN-002 (AXP000149.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000149.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.